US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

3.660 -0.290 (-7.34%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
News headline image
Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)
From Jaguar Health, Inc.
Via ACCESS Newswire
What's going on in today's session ↗
Via Chartmill
News headline image
Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Jaguar Health Compliant with Nasdaq Bid Price Rule
Via ACCESS Newswire
Jaguar Health Inc (NASDAQ:JAGX) Swings to Profit on Licensing Deal, But Market Sells the News ↗
Via Chartmill
News headline image
Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
Company Executives Share Strategic Vision and Engage with Investors Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention
From Jaguar Health, Inc.
Via ACCESS Newswire
News headline image
Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases
Via ACCESS Newswire
News headline image
Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders
Via ACCESS Newswire
News headline image
Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders
Via ACCESS Newswire
News headline image
Jaguar Health (JAGX) Q3 2025 Earnings Transcript ↗
Jaguar Health (JAGX) Q3 2025 Earnings Transcript 
Via The Motley Fool
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Jaguar Health Reports First Quarter 2026 Financials
Via ACCESS Newswire
News headline image
Jaguar (JAGX) Q4 2025 Earnings Transcript ↗
Jaguar (JAGX) Q4 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer
Via ACCESS Newswire
News headline image
Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule
Via ACCESS Newswire
News headline image
Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)
Via ACCESS Newswire
These stocks are moving in today's session ↗
Via Chartmill
Let's have a look at the top gainers and losers in the middle of the day of today's session. ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Monday's session. ↗
Via Chartmill
News headline image
Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health
Via ACCESS Newswire
News headline image
Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Via ACCESS Newswire
News headline image
Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split
Via ACCESS Newswire
News headline image
Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)
Via ACCESS Newswire
News headline image
Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders
Via ACCESS Newswire
News headline image
Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs
Via ACCESS Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >